Author:
Szucs-Reed Regina P.,Gallagher Rollin M.
Reference211 articles.
1. Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J. P., Opsomer, F., et al. (2000). Endocrine consequences of long-term intrathecal administration of opioids. The Journal of Clinical Endocrinology and Metabolism, 85, 2215–2222.
2. Amabile, C. M., & Bowman, B. J. (2006). Overview of oral modified-release opioid products for the management of chronic pain. The Annals of Pharmacotherapy, 40, 1327–1335.
3. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
4. American Psychiatric Association. (2011). DSM-5 development proposed revisions: Substance-related disorders. Washington, DC: American Psychiatric Association.
5. Apkarian, A. V., Sosa, Y., Sonty, S., Levy, R. M., Harden, R. N., et al. (2004). Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. The Journal of Neuroscience, 24, 10410–10415.